Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Ab928
2. 2239273-34-6
3. Ab-928
4. Etrumadenant
5. 3-(2-amino-6-(1-((6-(2-hydroxypropan-2-yl)pyridin-2-yl)methyl)-1h-1,2,3-triazol-4-yl)pyrimidin-4-yl)-2-methylbenzonitrile
6. Etrumadenant [usan]
7. W0ze0nt8if
8. 3-[2-amino-6-[1-[[6-(1-hydroxy-1-methylethyl)-2-pyridinyl]methyl]-1h-1,2,3-triazol-4-yl]-4-pyrimidinyl]-2-methylbenzonitrile
9. Trumadenant
10. Unii-w0ze0nt8if
11. A2ar/a2br Antagonist-1
12. Etrumadenant [inn]
13. Etrumadenant [who-dd]
14. Chembl4740383
15. Schembl20401465
16. Gtpl11154
17. Bcp33220
18. Ex-a3172
19. Mfcd32263040
20. Nsc823658
21. S9608
22. Who 11620
23. Zb1610
24. Akos037649091
25. Ab928 ; Ab 928
26. Nsc-823658
27. Ac-36346
28. Bs-16547
29. Hy-129393
30. Cs-0105184
31. D81385
32. Q66977586
33. Benzonitrile, 3-[2-amino-6-[1-[[6-(1-hydroxy-1-methylethyl)-2-pyridinyl]methyl]-1h-1,2,3-triazol-4-yl]-4-pyrimidinyl]-2-methyl-
| Molecular Weight | 426.5 g/mol |
|---|---|
| Molecular Formula | C23H22N8O |
| XLogP3 | 1.4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 5 |
| Exact Mass | 426.19165736 g/mol |
| Monoisotopic Mass | 426.19165736 g/mol |
| Topological Polar Surface Area | 139 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 680 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
Under the license agreement, Taiho will further support the development & commercialization of AB680 (quemliclustat) & will operationalize the PRISM-1 study in Japan as part of its mission.
Lead Product(s): Quemliclustat,Zimberelimab,Etrumadenant
Therapeutic Area: Oncology Brand Name: AB680
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Taiho Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 08, 2024
Lead Product(s) : Quemliclustat,Zimberelimab,Etrumadenant
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Taiho Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Taiho Exercises License Option for Quemliclustat in Japan and Asia
Details : Under the license agreement, Taiho will further support the development & commercialization of AB680 (quemliclustat) & will operationalize the PRISM-1 study in Japan as part of its mission.
Brand Name : AB680
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 08, 2024
Details:
Domvanalimab is an Fc-silent investigational monoclonal antibody that is designed to bind to TIGIT, a protein receptor on immune cells that acts as a brake on the immune response.
Lead Product(s): Etrumadenant,Zimberelimab
Therapeutic Area: Oncology Brand Name: AB154
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Arcus Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Lead Product(s) : Etrumadenant,Zimberelimab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Arcus Biosciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Domvanalimab is an Fc-silent investigational monoclonal antibody that is designed to bind to TIGIT, a protein receptor on immune cells that acts as a brake on the immune response.
Brand Name : AB154
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 19, 2022
Details:
Domvanalimab is an Fc-silent investigational monoclonal antibody that is designed to bind to TIGIT, a protein receptor on immune cells that acts as a brake on the immune response.
Lead Product(s): Etrumadenant,Zimberelimab
Therapeutic Area: Oncology Brand Name: AB154
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Arcus Bioscience
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2022
Lead Product(s) : Etrumadenant,Zimberelimab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Arcus Bioscience
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Domvanalimab is an Fc-silent investigational monoclonal antibody that is designed to bind to TIGIT, a protein receptor on immune cells that acts as a brake on the immune response.
Brand Name : AB154
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 28, 2022
Details:
ARC-7 and the ongoing ARC-10 Phase 3 registrational study will continue to enroll as planned, and preparations for additional Phase 3 studies are underway for domvanalimab-based combinations across various cancer types.
Lead Product(s): Domvanalimab,Zimberelimab,Etrumadenant
Therapeutic Area: Oncology Brand Name: AB154
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Gilead Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2021
Lead Product(s) : Domvanalimab,Zimberelimab,Etrumadenant
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Gilead Sciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ARC-7 and the ongoing ARC-10 Phase 3 registrational study will continue to enroll as planned, and preparations for additional Phase 3 studies are underway for domvanalimab-based combinations across various cancer types.
Brand Name : AB154
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 24, 2021
Details:
The Phase 1b clinical trial is a global multi-center, open-label trial of CERC-007 that will enroll around 12 subjects with active adult onset Still’s disease with a primal goal of the study will be to determine the safety and tolerability of CERC-007 in AOSD patients.
Lead Product(s): Eganelisib,Etrumadenant
Therapeutic Area: Oncology Brand Name: IPI-549
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Arcus Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2021
Lead Product(s) : Eganelisib,Etrumadenant
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Arcus Biosciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Infinity to Present at New York Academy of Sciences’ Frontiers in Cancer Immunotherapy 2021
Details : The Phase 1b clinical trial is a global multi-center, open-label trial of CERC-007 that will enroll around 12 subjects with active adult onset Still’s disease with a primal goal of the study will be to determine the safety and tolerability of CERC-007 ...
Brand Name : IPI-549
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 05, 2021
Details:
Under this agreement, Gilead Gains Broad Access to Arcus’s Clinical and Preclinical Pipeline of Immuno-Oncology Product Candidates that Target Critical Biological Pathways. Arcus to continue to independently conduct research on New Targets.
Lead Product(s): Zimberelimab,Etrumadenant,AB154
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Gilead Sciences
Deal Size: $2,000.0 million Upfront Cash: $175.0 million
Deal Type: Collaboration May 27, 2020
Lead Product(s) : Zimberelimab,Etrumadenant,AB154
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Gilead Sciences
Deal Size : $2,000.0 million
Deal Type : Collaboration
Details : Under this agreement, Gilead Gains Broad Access to Arcus’s Clinical and Preclinical Pipeline of Immuno-Oncology Product Candidates that Target Critical Biological Pathways. Arcus to continue to independently conduct research on New Targets.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : $175.0 million
May 27, 2020
Details:
Taiho’s in-licensing facilitates global development and commercialization of zimberelimab as a monotherapy and as a combination backbone for Arcus’s and Taiho’s oncology portfolios.
Lead Product(s): Zimberelimab,Etrumadenant,AB154
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Taiho Pharmaceutical
Deal Size: $275.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 26, 2020
Lead Product(s) : Zimberelimab,Etrumadenant,AB154
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Taiho Pharmaceutical
Deal Size : $275.0 million
Deal Type : Licensing Agreement
Arcus Biosciences and Taiho Pharmaceutical Announce Taiho’s Exercise of an Exclusive License to ...
Details : Taiho’s in-licensing facilitates global development and commercialization of zimberelimab as a monotherapy and as a combination backbone for Arcus’s and Taiho’s oncology portfolios.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
February 26, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Etrumadenant manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Etrumadenant, including repackagers and relabelers. The FDA regulates Etrumadenant manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Etrumadenant API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Etrumadenant supplier is an individual or a company that provides Etrumadenant active pharmaceutical ingredient (API) or Etrumadenant finished formulations upon request. The Etrumadenant suppliers may include Etrumadenant API manufacturers, exporters, distributors and traders.
Etrumadenant Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Etrumadenant GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Etrumadenant GMP manufacturer or Etrumadenant GMP API supplier for your needs.
A Etrumadenant CoA (Certificate of Analysis) is a formal document that attests to Etrumadenant's compliance with Etrumadenant specifications and serves as a tool for batch-level quality control.
Etrumadenant CoA mostly includes findings from lab analyses of a specific batch. For each Etrumadenant CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Etrumadenant may be tested according to a variety of international standards, such as European Pharmacopoeia (Etrumadenant EP), Etrumadenant JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Etrumadenant USP).
LOOKING FOR A SUPPLIER?
